Pasar al contenido principal

PAPEL FISIOLOGICO Y UTILIDAD TERAPEUTICA DEL RECEPTOR CANNABINOIDE CB2 EN MODELOS ANIMALES DE ANSIEDAD Y DEPRESION

SAF2008-01106

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2008
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Role of the endocannabinoid system in drug addiction

  • Manzanares, Jorge
  • Cabañero Ferri, David
  • Puente, Nagore
  • García-Gutiérrez, María S.
  • Grandes, Pedro
  • Maldonado, Rafael, 1961-
Drug addiction is a chronic relapsing disorder that produces a dramaticglobal health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsion and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches., We acknowledge the financial support of the Spanish MINECO (#SAF2017-84060-R-AEI/FEDER-UE), Instituto de Salud Carlos III-RETICS(##RD16/0017/0020), Ministerio de Sanidad, Servicios Sociales e Igualdad-Plan Nacional Sobre Drogas (#PNSD-2017I068), and the Generalitat de Catalunya-AGAUR ((#2017-SGR-669 and #ICREA Acadèmia2015) and the European Commission-DG RTD (#FP7-HEALTH-F2-2013-602891-NeuroPain) to RM. FEDER funding support is also acknowledged. This work was supported by Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU) (RD16/0017/0012), The Basque Government (BCG IT764-13) and MINECO/FEDER, UE(SAF2015-65034-R) to PG. This research was supported by Instituto de Salud Carlos III (RETICS, RD12/0028/0019, RD16/0017/0014 and RD06/0001/1004), Plan Nacional Sobre Drogas (PNSD 2016/016 and 2007/061), Ministerio de Economía y Competitividad (FIS, PI14/00438) and Ministerio de Ciencia e Innovación (SAF2008-01106) to JM
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Abnormal expression pattern of Notch receptors, ligands, and downstream effectors in the dorsolateral prefrontal cortex and amygdala of suicidal victims

  • Monsalve, Eva M.
  • García-Gutiérrez, María Salud
  • Navarrete, Francisco
  • Giner, Salvador
  • Laborda, Jorge
  • Manzanares, Jorge
Recent studies have associated alterations of neuronal plasticity in specific brain areas with suicidal behavior. The Notch signaling pathway plays a relevant role in the control of stem cell maintenance, cell migration, and neuronal plasticity. In the present study, the gene expression of the four Notch receptors (NOTCH1-4), the five canonical ligands (DLL1, DLL3, DLL4, JAGGED1, and JAGGED2), the two non-canonical ligands (DLK1 and DLK2), and the transcription factors (HES1, HEY1, and HEY2) were measured in the dorsolateral prefrontal cortex (DLPFC) and amygdala (AMY) of suicide victims (S; n = 13 males, with no clinical psychiatric history and non-treated with anxiolytic or antidepressant drugs) and their corresponding controls (C; n = 13 males) by real-time PCR. The results revealed a reduction of NOTCH2 and NOTCH1, NOTCH3, and NOTCH4 gene expression in the DLPFC and AMY of S compared with C, respectively. DLL1 levels were increased in the DLPFC and decreased in the AMY, whereas DLL4, JAGGED1, and JAGGED2 were significantly decreased in the regions analyzed. DLK1 was reduced in the AMY, whereas no changes were observed in the DLPFC and in DLK2 expression levels in any of the regions analyzed. HES1 was significantly reduced in both brain regions from S, whereas there were no significant changes in HEY1 and HEY2. This study provides evidence suggesting that the Notch signaling pathway could be a potential key target in the treatment of suicidal behaviors., This research was supported by grants from Ministry of Science and Innovation (SAF 2008–01106, RETICS RD12/0028/0019, and FEDER) and Ministry of Health (PNSD 2007/061). FN is a postdoctoral fellow of the RETICS RD12/0028/0019., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gene and protein alterations of FKBP5 and glucocorticoid receptor in the amygdala of suicide victims

  • Pérez-Ortiz, José Manuel
  • García-Gutiérrez, María Salud
  • Navarrete, Francisco
  • Giner, Salvador
  • Manzanares, Jorge
Recent reports suggest that FKBP5 gene and its corresponding FKBP5 protein play a relevant role in the regulation of anxiety and depression in animal models and human stress-related disorders. In the present study, FKBP5 and glucocorticoid receptor (GR) gene and protein expression were analyzed in the amygdala (AMY) of suicide victims (n = 13 males, without clinical psychiatric history and non-treated with anxiolytic or antidepressant drugs) and its corresponding controls (n = 13 males) by real-time PCR and Western blotting. The results revealed that FKBP5 and GR gene expression were significantly reduced in the AMY (−38% and −48%, respectively) of suicide victims compared with controls. Interestingly, FKBP5 and GR protein expression were also significantly decreased (−41% and −42%, respectively) in the AMY of suicide victims compared with controls. These results suggest that the FKBP5 plays a relevant role in human emotional responses and suggest this receptor as a new promising target in the treatment of suicide behavior., This research was supported by grants from Ministry of Science and Innovation (SAF 2008-01106 and RETICS RD06/0001/1004), Ministry of Health (PNSD 2007/061) and “Red Temática de Investigación Cooperativa en Salud” (RETICS, Instituto de Salud Carlos III, MICINN and FEDER, Madrid, Spain, “Red de Trastornos Adictivos”, RD06/0001/1004). JMP-O is a postdoctoral fellow supported by FISCAM (Fundación para la investigación sanitaria en Castilla La Mancha). FN is a predoctoral fellow of the Ministry of Education., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors

  • García-Gutiérrez, María Salud
  • Ortega-Álvaro, Antonio
  • Busquets-García, Ana
  • Pérez-Ortiz, José Manuel
  • Caltana, Laura
  • Ricatti, María Jimena
  • Brusco, Alicia
  • Maldonado, Rafael
  • Manzanares, Jorge
In this study, the role of CB2r on aversive memory consolidation was further evaluated. Mice lacking CB2r (CB2KO) and their corresponding littermates (WT) were exposed to the step-down inhibitory avoidance test (SDIA). MAP2, NF200 and synaptophysin (SYN)-immunoreactive fibers were studied in the hippocampus (HIP) of both genotypes. The number of synapses, postsynaptic density thickness and the relation between the synaptic length across the synaptic cleft and the distance between the synaptic ends were evaluated in the HIP (dentate gyrus (DG) and CA1 fields) by electron microscopy. Brain-derived neurotrophic factor (BDNF), glucocorticoid receptor (NR3C1) gene expressions and mTOR/p70S6K signaling cascade were evaluated in the HIP and prefrontal cortex (PFC). Finally, the effects of acute administration of CB2r-agonist JWH133 or CB2r-antagonist AM630 on memory consolidation were evaluated in WT mice by using the SDIA. The lack of CB2r impaired aversive memory consolidation, reduced MAP2, NF200 and SYN-immunoreactive fibers and also reduced the number of synapses in DG of CB2KO mice. BDNF and NR3C1 gene expression were reduced in the HIP of CB2KO mice. An increase of p-p70S6K (T389 and S424) and p-AKT protein expression was observed in the HIP and PFC of CB2KO mice. Interestingly, administration of AM630 impaired aversive memory consolidation, whereas JWH133 enhanced it. Further functional and molecular assessments would have been helpful to further support our conclusions. These results revealed that CB2r are involved in memory consolidation, suggesting that this receptor could be a promising target for developing novel treatments for different cognitive impairment-related disorders., This research was supported by grants from Ministry of Science and Innovation (SAF 2008-01106 and RETICS RD06/0001/1004), Ministry of Health (PNSD 2007/061) and “Red Temática de Investigación Cooperativa en Salud” (RETICS, Instituto de Salud Carlos III, MICINN and FEDER, Madrid, Spain, “Red de Trastornos Adictivos”, RD06/0001/1004) to JM, and Grant UBACYT 00093 (to AB). JMP-O is a postdoctoral fellow supported by FISCAM (Fundación para la investigación sanitaria en Castilla La Mancha). MSG-G is a predoctoral fellow of the Ministry of Science and Innovation., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of the endocannabinoid system in drug addiction

  • Manzanares, Jorge
  • Cabañero Ferri, David
  • Puente, Nagore
  • García-Gutiérrez, María S.
  • Grandes, Pedro
  • Maldonado, Rafael, 1961-
Drug addiction is a chronic relapsing disorder that produces a dramaticglobal health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsion and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches., We acknowledge the financial support of the Spanish MINECO (#SAF2017-84060-R-AEI/FEDER-UE), Instituto de Salud Carlos III-RETICS(##RD16/0017/0020), Ministerio de Sanidad, Servicios Sociales e Igualdad-Plan Nacional Sobre Drogas (#PNSD-2017I068), and the Generalitat de Catalunya-AGAUR ((#2017-SGR-669 and #ICREA Acadèmia2015) and the European Commission-DG RTD (#FP7-HEALTH-F2-2013-602891-NeuroPain) to RM. FEDER funding support is also acknowledged. This work was supported by Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU) (RD16/0017/0012), The Basque Government (BCG IT764-13) and MINECO/FEDER, UE(SAF2015-65034-R) to PG. This research was supported by Instituto de Salud Carlos III (RETICS, RD12/0028/0019, RD16/0017/0014 and RD06/0001/1004), Plan Nacional Sobre Drogas (PNSD 2016/016 and 2007/061), Ministerio de Economía y Competitividad (FIS, PI14/00438) and Ministerio de Ciencia e Innovación (SAF2008-01106) to JM